VX-702

Catalog No.S6005

For research use only.

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

VX-702 Chemical Structure

CAS No. 745833-23-2

Selleck's VX-702 has been cited by 32 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Other p38 MAPK Products

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell NIS4WpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVey[GxbUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzNUSzJO69VQ>? MlzKV2FPT0WU
human NCI-H720 cell M2fx[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\jTXBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMU[4NkDPxE1? M{jQN3NCVkeHUh?=
JVM-2 cell M1z2Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGDy[GRKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDNizszN MXrTRW5ITVJ?
human NCI-H69 cell M4nBPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1vkdWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODl7NEGg{txO M{nnWXNCVkeHUh?=
human BV-173 cell NIXXPHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlvyTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOzh4IN88US=> NYeyW2d7W0GQR1XS
human KU812 cell NF;ifZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3XyWmlvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPDh6IN88US=> MYfTRW5ITVJ?
human DU-145 cell NUXRbGo6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnvQTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1PTV2IN88US=> NEWxdGpUSU6JRWK=
KARPAS-45 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXv1W5NZUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?= M2n4bnNCVkeHUh?=
human AGS cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTJVnZpUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjVzIN88US=> MUnTRW5ITVJ?
human MOLT-13 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1PnVmlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEGg{txO NX;LVWZqW0GQR1XS
human NCI-H209 cell MmPUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2W2e2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO NULvZm9oW0GQR1XS
human CTV-1 cell NGfDUm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPhSWxKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDN6OTFOwG0> M{TobXNCVkeHUh?=
LU-139 cell Mly0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYX4d3V6UW6qaXLpeIlwdiCxZjDoeY1idiCOVT2xN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF7NEO1JO69VQ>? MmTUV2FPT0WU
ML-2 cell NXnkUZlNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXPhXYUxUW6qaXLpeIlwdiCxZjDoeY1idiCPTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOjZ4MTFOwG0> NEHaeJJUSU6JRWK=
human K5 cell NXLReHR1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGPleWFKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlkyPyEQvF2= NFWxeldUSU6JRWK=
human SBC-1 cell NWHXdXQ1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUDSfIg3UW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> MkPXV2FPT0WU
human COR-L88 cell NGLKcZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3G5UGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2ODFOwG0> NYjT[GZ5W0GQR1XS
human KY821 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1[yU2lvcGmkaYTpc44hd2ZiaIXtZY4hU1l6MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM6PjB|IN88US=> NHXQcYVUSU6JRWK=
human HCC2218 cell M4nyXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFi4eWtKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR7N{K4JO69VQ>? MnPaV2FPT0WU
human ECC10 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWjGS2FqUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjV|OEmg{txO MV3TRW5ITVJ?
human EW-3 cell NVKzOpV4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlTOTY5pcWKrdHnvckBw\iCqdX3hckBGXy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OlYyOSEQvF2= M1\IWHNCVkeHUh?=
human EW-18 cell M3HZO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;QTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|Q3PzlizszN NXTzTXF4W0GQR1XS
human UACC-257 cell NGWyXVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLFenFGUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMkCzNlYh|ryP MnKyV2FPT0WU
human G-361 cell NI\SSpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlnPTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN NVq1RXluW0GQR1XS
human HMV-II cell NITpOpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGLVSoVKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO MnPmV2FPT0WU
human DEL cell NXHk[YxKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVnUT|BSUW6qaXLpeIlwdiCxZjDoeY1idiCGRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlIxPzB2IN88US=> M{XPN3NCVkeHUh?=
human IGROV-1 cell NEmyUlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NImxc|lKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR|MUi4JO69VQ>? MoXZV2FPT0WU
human SK-OV-3 cell MnHCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NI\SeoRKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZzNkm3JO69VQ>? M4jIfHNCVkeHUh?=
human LAMA-84 cell NWTUemQ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVPCOoxVUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55MUK4OEDPxE1? M1zsVnNCVkeHUh?=
human NCI-H510A cell NIX4R4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUGwRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTJ3Mk[g{txO M1\0W3NCVkeHUh?=
human CP66-MEL cell NFrqR|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3jP[WlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl|NUW5JO69VQ>? M4TlcnNCVkeHUh?=
human HAL-01 cell NXzVUWExT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVr1dnNEUW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ5OUG4JO69VQ>? MmDZV2FPT0WU
human RS4-11 cell  NXPvRoRzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWPJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|A2PzNizszN MYHTRW5ITVJ?
human RPMI-8226 cell M3fqXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJ|N{[g{txO MYHTRW5ITVJ?
human NCI-H82 cell MkX1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MljjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45QTNyNTFOwG0> MVrTRW5ITVJ?
human NY cells MkHJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUXLNIxXUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlc3OzdizszN NGX4XplUSU6JRWK=
human MDA-MB-361 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVm4WJBJUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60N|E2QCEQvF2= Ml22V2FPT0WU
human MOLT-4 cell Ml;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUPtXFFRUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>? Ml;UV2FPT0WU
human DU-4475 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2e5OGlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODV3NkWg{txO MnLKV2FPT0WU
human ESS-1 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHSfWVKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zQTF5OTFOwG0> M4jDSHNCVkeHUh?=
human NCI-H1299 cell NX;pe3I2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV[yPGZ4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEzQTliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNFM{KM7:TR?= NVXYWWxTW0GQR1XS
human COLO-684 cell NUTMVWo2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42QDF4NTFOwG0> NYXOR5AxW0GQR1XS
human MV-4-11 cell MnvTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XKcWlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzFzOUmg{txO MXPTRW5ITVJ?
human D-542MG cell M2mzfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlM6Ojd{IN88US=> M1zzO3NCVkeHUh?=
human A4-Fuk cell NIT0eXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGE1NU[3azDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFM3PjJizszN M4TkbHNCVkeHUh?=
human HL-60 cell MoXYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVvTUoViUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO NYThUVRDW0GQR1XS
human NCI-H526 cell M3P2WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGD0R3BKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py53OUiwNUDPxE1? NYPRd5VXW0GQR1XS
human L-363 cell M1fpfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz63PVI2OiEQvF2= MUnTRW5ITVJ?
human A388 cell Mnr5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XsZmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFA{QDRizszN M4XMS3NCVkeHUh?=
human MS-1 NVTnPIhpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1UNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkizOFY2KM7:TR?= NX3qbGY4W0GQR1XS
human JAR cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYPJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwOES5NlMh|ryP NXX5SVRlW0GQR1XS
human TI-73 cell MmPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJHRKNTd|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD6wOlIzKM7:TR?= MVTTRW5ITVJ?
human CTB-1 cell M4XlUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn:xTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNVc5OjVizszN MoLyV2FPT0WU
human SK-NEP-1 cell MmDkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOzB|ODFOwG0> NXW0T3dEW0GQR1XS
human HT-29 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFrwcGZKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTFzMTFOwG0> M{K1d3NCVkeHUh?=
human NCI-H1092 cell NH\nb|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkLNTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC5|MUig{txO MkHzV2FPT0WU
human KMOE-2 cell NUizfndqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEfVOJNKdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO NXHLW4tKW0GQR1XS
human EM-2 cell NV\zVFVzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFW1dpdKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4zQDRzIN88US=> NHzNTWpUSU6JRWK=
human RT-112 cell M1rv[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LldmlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOzl6NDFOwG0> MYnTRW5ITVJ?
human DB cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTVwOEWxN{DPxE1? Mki5V2FPT0WU
human NCI-H1770 cell MlX5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVjHbGRVUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= NXvFNJR{W0GQR1XS
human CAL-54 cell Mn[2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;qXINKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd|IN88US=> NX7FOG1TW0GQR1XS
human NB14 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmjyTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUeuOlM6PSEQvF2= NXq5cZdWW0GQR1XS
human RPMI-7951 cell NFm1TG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWTtXJpEUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT6xO|g{KM7:TR?= Mn;LV2FPT0WU
human T47D cell NV62fYpXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnr4TY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlI1OyEQvF2= MUjTRW5ITVJ?
human A549 cell MnPPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHSwfIxKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zQDFzIN88US=> MWHTRW5ITVJ?
human A2780 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV71V3FEUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjh{MkWg{txO M1[3XnNCVkeHUh?=
human SK-MEL-24 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjEOoVKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN|LkCzNVEh|ryP MU\TRW5ITVJ?
In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 81 mg/mL
(200.34 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
For best results, use promptly after mixing.

4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Drug: VX-702 Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor